Literature DB >> 35041016

One-year mortality after ICU admission due to COVID-19 infection.

Adrian Ceccato1,2,3,4, Raquel Pérez-Arnal5, Anna Motos1,2,3, Ferran Barbé1,6, Antoni Torres7,8,9,10,11.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35041016      PMCID: PMC8764887          DOI: 10.1007/s00134-021-06611-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Dear Editor, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes severe disease in some patients. Patients can experience severe disabilities after intensive care unit (ICU) admission due to coronavirus disease 2019 (COVID-19) [1]. Nevertheless, it remains unclear how these consequences may increase mortality. Therefore, we aimed to evaluate 1-year mortality in a large cohort of patients in Spain who required ICU admission due to COVID-19. This is a multicenter, observational and prospective/retrospective study of patients admitted to 60 Spanish ICUs (eTable1) due to COVID-19 infection [2]. The study was approved by the institution’s internal review board and registered as NCT04457505. The main outcome was 1-year mortality, which was defined as death during hospitalization or at one point during 1-year follow-up since ICU admission. Patients included in this cohort were either visited or called during this follow-up period to determine survival status. Of the 3249 patients admitted between February 28 and July 31, 2020, 3210 patients completed 1-year follow-up since ICU admission. Baseline characteristics and complications during ICU admissions are summarized in eTable2. In-hospital mortality rate was 34% (n = 1102); 1% of patients (n = 28) died after hospital discharge (Fig. 1) (eFig1). One-year mortality was 14% and 40% in non-invasive ventilated patients (83 of 592 patients) and patients receiving invasive mechanical ventilation (1000 of 2507 patients), respectively. The main causes of death after hospital discharge were out-of-hospital cardiac arrest (10 patients, 37%); infectious diseases (six patients, 21%); and respiratory failure (six patients, 21%) (eTable3). In total, 205 patients visited the emergency department, and 67 patients required readmission after hospital discharge (Fig. 1). The median number of days between hospital admission and mortality in those patients who died while not in hospital was 145 (interquartile range 39–215).
Fig. 1

Relation of readmissions and death during 1-year follow-up. Panel A: Time to death or readmission since hospital discharge. n = 28 for mortality and n = 67 for readmissions. Panel B: Time to death since hospital admission during 1-year follow-up. N = 1130. Median time between admission and death was 17 days [Q1 = 9- Q3 = 30]. For in-hospital mortality, the median was 17 days [Q1 = 9- Q3 29]; the median for deaths after discharge was 145.5 days, [Q1 39- Q3 215.5]

Relation of readmissions and death during 1-year follow-up. Panel A: Time to death or readmission since hospital discharge. n = 28 for mortality and n = 67 for readmissions. Panel B: Time to death since hospital admission during 1-year follow-up. N = 1130. Median time between admission and death was 17 days [Q1 = 9- Q3 = 30]. For in-hospital mortality, the median was 17 days [Q1 = 9- Q3 29]; the median for deaths after discharge was 145.5 days, [Q1 39- Q3 215.5] In this study, we found that 1-year mortality was 35% for patients admitted to the ICU for COVID-19. Only 1% of patients discharged died within the first year of follow-up. Mortality observed after hospital discharge was lower than that reported in other studies on COVID-19 [3]. When compared with other causes of pneumonia, long-term mortality related to COVID-19 is lower as well. Indeed, mortality rates in severe community-acquired pneumonia rose from 27% at 30 days to 47% at 1 year [4], mainly due to cardiovascular events [5]. Mortality rates did not increase despite the well-known fact that severe COVID-19 causes disabilities as a result of post-intensive care syndrome and long COVID [1]. The reason as to why these patients had lower mortality and readmissions after discharge remains unclear; however, close follow-up, fewer comorbidities and less cardiovascular sequelae may provide an explanation for such an observation. Hospital-acquired pneumonia was more common in those patients who died after hospital discharge in comparison to patients who survived after 1-year follow-up, indicating a potential marker of poor prognosis. The main limitation of this report is the inclusion of patients from the first wave of the pandemic when the healthcare system was overwhelmed. The main strength of this study is the presentation of well-collected data from a nationwide cohort, including out-of-hospital deaths; there were few missing data in terms of follow-up. In conclusion, among patients admitted to the ICU for COVID-19 and who were later discharged alive, only 1% of these individuals died during the 1-year follow-up period. Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 51 KB)
  5 in total

Review 1.  Cardiovascular Events After Community-Acquired Pneumonia: A Global Perspective with Systematic Review and Meta-Analysis of Observational Studies.

Authors:  António Tralhão; Pedro Póvoa
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

2.  Long-term mortality of elderly patients after intensive care unit admission for COVID-19.

Authors:  Antoine Guillon; Emeline Laurent; Lucile Godillon; Antoine Kimmoun; Leslie Grammatico-Guillon
Journal:  Intensive Care Med       Date:  2021-04-12       Impact factor: 17.440

3.  The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States.

Authors:  Rodrigo Cavallazzi; Stephen Furmanek; Forest W Arnold; Leslie A Beavin; Richard G Wunderink; Michael S Niederman; Julio A Ramirez
Journal:  Chest       Date:  2020-04-13       Impact factor: 10.262

4.  Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort.

Authors:  Jessica González; Iván D Benítez; Paola Carmona; Sally Santisteve; Aida Monge; Anna Moncusí-Moix; Clara Gort-Paniello; Lucía Pinilla; Amara Carratalá; María Zuil; Ricard Ferrer; Adrián Ceccato; Laia Fernández; Ana Motos; Jordi Riera; Rosario Menéndez; Dario Garcia-Gasulla; Oscar Peñuelas; Jesús F Bermejo-Martin; Gonzalo Labarca; Jesus Caballero; Gerard Torres; David de Gonzalo-Calvo; Antoni Torres; Ferran Barbé
Journal:  Chest       Date:  2021-03-04       Impact factor: 9.410

  5 in total
  3 in total

1.  Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study.

Authors:  Massimiliano Greco; Thomas De Corte; Ari Ercole; Massimo Antonelli; Elie Azoulay; Giuseppe Citerio; Andy Conway Morris; Gennaro De Pascale; Frantisek Duska; Paul Elbers; Sharon Einav; Lui Forni; Laura Galarza; Armand R J Girbes; Giacomo Grasselli; Vitaly Gusarov; Alasdair Jubb; Jozef Kesecioglu; Andrea Lavinio; Maria Cruz Martin Delgado; Johannes Mellinghoff; Sheila Nainan Myatra; Marlies Ostermann; Mariangela Pellegrini; Pedro Povoa; Stefan J Schaller; Jean-Louis Teboul; Adrian Wong; Jan J De Waele; Maurizio Cecconi
Journal:  Intensive Care Med       Date:  2022-05-21       Impact factor: 41.787

2.  Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units.

Authors:  Antoni Torres; Anna Motos; Adrián Ceccato; Jesús Bermejo-Martin; David de Gonzalo-Calvo; Raquel Pérez; Marta Barroso; Ion Zubizarreta Pascual; Jessica Gonzalez; Laia Fernández-Barat; Ricard Ferrer; Jordi Riera; Dario García-Gasulla; Oscar Peñuelas; José Ángel Lorente; Raquel Almansa; Rosario Menéndez; Kasra Kiarostami; Joan Canseco; Rosario Amaya Villar; José M Añón; Ana Balan Mariño; Carme Barberà; José Barberán; Aaron Blandino Ortiz; Maria Victoria Boado; Elena Bustamante-Munguira; Jesús Caballero; María Luisa Cantón-Bulnes; Cristina Carbajales Pérez; Nieves Carbonell; Mercedes Catalán-González; Raúl de Frutos; Nieves Franco; Cristóbal Galbán; Víctor D Gumucio-Sanguino; María Del Carmen de la Torre; Emili Díaz; Ángel Estella; Elena Gallego; José Luis García Garmendia; José M Gómez; Arturo Huerta; Ruth Noemí Jorge García; Ana Loza-Vázquez; Judith Marin-Corral; María Cruz Martin Delgado; Amalia Martínez de la Gándara; Ignacio Martínez Varela; Juan López Messa; Guillermo M Albaiceta; Maite Nieto; Mariana Andrea Novo; Yhivian Peñasco; Felipe Pérez-García; Juan Carlos Pozo-Laderas; Pilar Ricart; Víctor Sagredo; Ángel Sánchez-Miralles; Susana Sancho Chinesta; Mireia Serra-Fortuny; Lorenzo Socias; Jordi Solé-Violan; Fernando Suárez-Sipmann; Luis Tamayo Lomas; José Trenado; Alejandro Úbeda; Luis Jorge Valdivia; Pablo Vidal; Ferran Barbé
Journal:  Arch Bronconeumol       Date:  2022-04-15       Impact factor: 6.333

3.  Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: A hospital-based observational study.

Authors:  Mariko Hanafusa; Nobutoshi Nawa; Yuki Goto; Tomoki Kawahara; Shigeru Miyamae; Yutaka Ueki; Nobuyuki Nosaka; Kenji Wakabayashi; Shuji Tohda; Ukihide Tateishi; Takeo Fujiwara
Journal:  J Med Virol       Date:  2022-09-23       Impact factor: 20.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.